PD-L1 expressing tumors have been linked to poorer outcomes in GC patients [54] but represent a promising population for the use of anti-PD-L1 (atezolizumab, durvalumab, avelumab) or anti-PD1 (nivolumab, pembrolizumab, sintilimab, tislelizumab, retifanlimab) antibody therapies. The gene discussed is CD274; the disease is gastric cancer.